• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Expanded mRNA Patent Suits Against Pfizer Involving BioNTech’s LNP Technology Might Change The Case For Investing In BioNTech (BNTX)

    Simply Wall St·07/28/2026 00:30:51
    Listen to the news
    • In July 2026, Arbutus Biopharma and Genevant Sciences filed three new international patent lawsuits against Pfizer and BioNTech, seeking injunctions and monetary relief over alleged infringement of lipid nanoparticle technology used in COVID-19 mRNA vaccines across Canada and multiple European markets.
    • These expanded legal actions add a complex layer of patent and operational risk for BioNTech, as they target core vaccine technology while Arbutus benefits from a US$178 million payment tied to a separate Moderna litigation settlement.
    • We’ll now examine how this broadened patent dispute, and the risk of injunctions on mRNA-LNP COVID-19 vaccines, reshapes BioNTech’s investment narrative.

    Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

    BioNTech Investment Narrative Recap

    To own BioNTech today, you need to believe its heavy investment in oncology can offset shrinking COVID-19 vaccine dependence and persistent losses. The new Arbutus/Genevant LNP lawsuits add a fresh layer of uncertainty around key COVID-19 products and cash flows, potentially complicating what is already the most important short term catalyst: clear evidence that pipeline assets can one day support the business without pandemic-era revenues. This legal overhang now sits alongside execution and funding risk in late-stage programs.

    Against this backdrop, BioNTech’s May 2026 ASCO updates on pumitamig (BNT327) stand out. The strong interim lung cancer data, along with multiple ongoing Phase 3 ROSETTA trials and combination plans, highlight why many investors see oncology as the core medium term value driver. These data points were helping to shift attention away from COVID-19 toward a future multi-product cancer franchise, even as the company remains unprofitable and reliant on legacy vaccine cash flows.

    But while oncology progress is encouraging, the expanding LNP litigation is a risk investors should be aware of, especially if you are counting on...

    Read the full narrative on BioNTech (it's free!)

    BioNTech's narrative projects €2.3 billion revenue and €445.7 million earnings by 2029. This requires a 5.8% yearly revenue decline and about a €1.7 billion earnings increase from -€1.3 billion today.

    Uncover how BioNTech's forecasts yield a $123.65 fair value, a 36% upside to its current price.

    Exploring Other Perspectives

    BNTX 1-Year Stock Price Chart
    BNTX 1-Year Stock Price Chart

    Some of the most optimistic analysts were expecting BioNTech’s revenue to reach about €3.2 billion and earnings of roughly €607 million by 2029, yet this bullish story of oncology-led growth and mRNA platform strength now has to be reconsidered in light of fresh LNP patent injunction risks that could challenge both the consensus and the more aggressive upside views.

    Explore 6 other fair value estimates on BioNTech - why the stock might be worth over 5x more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • Our free BioNTech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioNTech's overall financial health at a glance.

    Interested In Other Possibilities?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.